This GeCIP sub-domain will use available suites of software to evaluate the druggable genome for rare disease and cancer discoveries made by the 100,000 Genomes Project. The approach taken by this sub-domain will be to take advantage of major initiatives with extant industry interest such as the Open PHACTS suite of software and the Structural Genomics Consortium as any development will require their involvement.
Open PHACTS (Mike Barnes): A recent approach to address these issues is the integration of data from multiple different sources by means of semantic web technologies has led to the Open Pharmacological Concepts Triple Store (Open PHACTS) is an Innovative Medicines Initiative Knowledge Management project (IMI - 2nd call 2009). The Open PHACTS Discovery Platform offers a software suite include ChEBI, ChEMBL, SureChEMBL, ChemSpider, ConceptWiki, DisGeNET, DrugBank, Gene Ontology, neXtProt, UniProt and WikiPathways. By drawing together multiple sources of publicly-available biomolecular, pharmacological and physicochemical data, Open PHACTS offers a state of the art platform that responds to structured, well defined queries in a meaningful and reproducible way. This was created from an Innovative Medicines Initiative so has significant industrial buy in so could provide a within Genomics England package to prime genomic therapeutic discovery.
The CanSAR software suite (http://cansar.icr.ac.uk) created by Bissan Al Lakzani is a publicly available, multidisciplinary, cancer-focused knowledgebase which integrates genomic, protein, pharmacological, drug and chemical data with structural biology, protein networks and druggability data. It is used by 150,000 people worldwide to rapidly access information and help interpret experimental data in a translational and drug discovery context. canSAR's aim is to provide comprehensive multidisciplinary annotation for genes and biological systems to enable target validation and drug discovery in canSAR. http://cansar.icr.ac.uk/cansar/data-sources/).
The Structural Genomics Consortium – Chas Bountra (Oxford). This initiative is funded by AbbVie, Bayer, Boehringer Ingelheim, Genome Canada through Ontario Genomics Institute Grant, GlaxoSmithKline, Janssen, Lilly Canada, Merck, Novartis Research Foundation, the Ontario Government, Pfizer, Takeda, and Wellcome Trust funding. This is a large-scale pre-competitive consortium that catalyses research in new areas drug discovery focusing explicitly on less wellstudied areas of the human genome. They have major programmes in DNA methylation, structural biology, target characterisation and recombinant antibodies. They have deposited more than 1500 high-resolution structures of medically relevant human proteins in public databases and generated 100’s of recombinant antibodies with therapeutic potential.